Nektar TherapeuticsNKTR
About: Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Employees: 137
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
4,260% more call options, than puts
Call options by funds: $218K | Put options by funds: $5K
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
30% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 37
4% more funds holding
Funds holding: 139 [Q3] → 145 (+6) [Q4]
4.84% less ownership
Funds ownership: 77.13% [Q3] → 72.3% (-4.84%) [Q4]
33% less capital invested
Capital invested by funds: $184M [Q3] → $124M (-$60.1M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Oppenheimer Jay Olson 20% 1-year accuracy 16 / 79 met price target | 810%upside $6 | Outperform Upgraded | 14 Mar 2025 |
HC Wainwright & Co. Arthur He 14% 1-year accuracy 3 / 22 met price target | 886%upside $6.50 | Buy Reiterated | 13 Mar 2025 |
B. Riley Securities Mayank Mamtani 14% 1-year accuracy 3 / 22 met price target | 507%upside $4 | Buy Initiated | 8 Jan 2025 |
Financial journalist opinion
Based on 8 articles about NKTR published over the past 30 days
